Is Chugai Pharma (4519) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 6.3% / 30% | 2.1% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 6.3% / 33% | 2.1% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 45.1% / 33% | 15.1% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 6.3% / 33% | 2.1% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 45.1% / 33% | 15.1% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 71.1% | |
| Operating Margin | 49.2% | |
| Net Margin | 34.5% | |
| Return on Equity (ROE) | 22.1% | |
| Return on Assets (ROA) | 15.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $447.6B |
| Free Cash Flow | $392.7B |
| Current Ratio | 4.2 |
| Total Assets | $2.2T |
Price & Trading
| Last Close | JPY 8,451.00 |
| 50-Day MA | JPY 9,070.32 |
| 200-Day MA | JPY 7,773.83 |
| Avg Volume | 2.3M |
| Beta | 0.5 |
|
52-Week Range
JPY 5,942.00
| |
About Chugai Pharma (4519)
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Chugai Pharma (4519) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Chugai Pharma is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Chugai Pharma's debt ratio?
Chugai Pharma's debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Chugai Pharma's key financial metrics?
Chugai Pharma has a market capitalization of $14.1T, trailing P/E ratio of 32.4. The company maintains a gross margin of 71.1% and a net margin of 34.5%. Return on equity stands at 22.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.